The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
Identifieur interne : 001B51 ( Main/Exploration ); précédent : 001B50; suivant : 001B52The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
Auteurs : Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-10-15.
English descriptors
- KwdEn :
Abstract
Reduction in the antiparkinsonian benefit of levodopa is a major complication of long‐term levodopa treatment in advanced Parkinson's disease (PD). Such loss of benefit arises because of reduced duration of action and appearance of disabling dyskinesia. We assess the potential of the α2 adrenergic antagonist fipamezole to reduce motor complications in parkinsonian macaques. MPTP‐lesioned macaques were treated acutely with fipamezole (10 mg/kg) alone and in combination with two doses of levodopa. Fipamezole extended both duration and quality of antiparkinsonian action of levodopa. Duration of antiparkinsonian action, on time, was increased by up to 75% while “good‐quality” on time, i.e., that not associated with disabling dyskinesia, was increased by up to 98%. Combination of fipamezole with the lower dose of levodopa provided antiparkinsonian benefit at least equivalent to that provided by the higher dose levodopa alone. However, with the combination, antiparkinsonian benefit was of much better quality. The proportion of on time without disabling dyskinesia (79%) was significantly greater than that with high dose levodopa alone (45%). Increased duration and quality of levodopa action may represent therapeutically valuable actions of α2 adrenergic antagonists. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23172
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000778
- to stream Istex, to step Curation: 000778
- to stream Istex, to step Checkpoint: 000537
- to stream Main, to step Merge: 001C64
- to stream Main, to step Curation: 001B51
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates</title><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></author><author><name sortKey="Piggott, Matthew J" sort="Piggott, Matthew J" uniqKey="Piggott M" first="Matthew J." last="Piggott">Matthew J. Piggott</name></author><author><name sortKey="Savola, Juha Atti" sort="Savola, Juha Atti" uniqKey="Savola J" first="Juha-Matti" last="Savola">Juha-Matti Savola</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4E8B3F2D498175868E71541171B4E4D4AD3F0E05</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23172</idno><idno type="url">https://api-v5.istex.fr/document/4E8B3F2D498175868E71541171B4E4D4AD3F0E05/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000778</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000778</idno><idno type="wicri:Area/Istex/Curation">000778</idno><idno type="wicri:Area/Istex/Checkpoint">000537</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000537</idno><idno type="wicri:doubleKey">0885-3185:2010:Johnston T:the:adrenergic:antagonist</idno><idno type="wicri:Area/Main/Merge">001C64</idno><idno type="wicri:Area/Main/Curation">001B51</idno><idno type="wicri:Area/Main/Exploration">001B51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates</title><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging, and Behaviour – Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Piggott, Matthew J" sort="Piggott, Matthew J" uniqKey="Piggott M" first="Matthew J." last="Piggott">Matthew J. Piggott</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, Crawley, Western Australia</wicri:regionArea><wicri:noRegion>Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Savola, Juha Atti" sort="Savola, Juha Atti" uniqKey="Savola J" first="Juha-Matti" last="Savola">Juha-Matti Savola</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Santhera Pharmaceuticals (Switzerland) Ltd, Liestal</wicri:regionArea><wicri:noRegion>Liestal</wicri:noRegion></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Brain, Imaging, and Behaviour – Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, 399 Bathurst Street, Mc‐11‐419, Toronto M5T2S7, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-10-15">2010-10-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2084">2084</biblScope><biblScope unit="page" to="2093">2093</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4E8B3F2D498175868E71541171B4E4D4AD3F0E05</idno><idno type="DOI">10.1002/mds.23172</idno><idno type="ArticleID">MDS23172</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MPTP primate</term><term>Parkinson's disease</term><term>dyskinesia</term><term>on time</term><term>wearing‐off</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Reduction in the antiparkinsonian benefit of levodopa is a major complication of long‐term levodopa treatment in advanced Parkinson's disease (PD). Such loss of benefit arises because of reduced duration of action and appearance of disabling dyskinesia. We assess the potential of the α2 adrenergic antagonist fipamezole to reduce motor complications in parkinsonian macaques. MPTP‐lesioned macaques were treated acutely with fipamezole (10 mg/kg) alone and in combination with two doses of levodopa. Fipamezole extended both duration and quality of antiparkinsonian action of levodopa. Duration of antiparkinsonian action, on time, was increased by up to 75% while “good‐quality” on time, i.e., that not associated with disabling dyskinesia, was increased by up to 98%. Combination of fipamezole with the lower dose of levodopa provided antiparkinsonian benefit at least equivalent to that provided by the higher dose levodopa alone. However, with the combination, antiparkinsonian benefit was of much better quality. The proportion of on time without disabling dyskinesia (79%) was significantly greater than that with high dose levodopa alone (45%). Increased duration and quality of levodopa action may represent therapeutically valuable actions of α2 adrenergic antagonists. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>Suisse</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></country><country name="Australie"><noRegion><name sortKey="Piggott, Matthew J" sort="Piggott, Matthew J" uniqKey="Piggott M" first="Matthew J." last="Piggott">Matthew J. Piggott</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Savola, Juha Atti" sort="Savola, Juha Atti" uniqKey="Savola J" first="Juha-Matti" last="Savola">Juha-Matti Savola</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4E8B3F2D498175868E71541171B4E4D4AD3F0E05
|texte= The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
}}
| This area was generated with Dilib version V0.6.29. |  |